Posted by Adam Awdish on
Human Total Factor VIII ELISA Kit from Innovative Research was used in the following study:
Kiruphagaran Thangaraju, Upendra Katneni, Imo J. Akpan, Kenichi Tanaka, Tiffany Thomas, Saini Setua, Julie A. Reisz, Francesca Cendali, Fabia Gamboni, Travis Nemkov, Stacie Kahn, Alexander Z. Wei, Jacob E. Valk, Krystalyn E. Hudson, David J. Roh, Chiara Moriconi, James C. Zimring, Angelo D'Alessandro, Steven L. Spitalnik, Richard O. Francis, and Paul W. Buehler
Frontiers in Medicine
January 10, 2022
COVID-19 infection results in a range of conditions, one of which is coagulopathy that varies in severity in association with the infection progression. Along with coagulopathy, venous thrombosis, thromboembolism, and arterial thrombosis have all been observed at elevated levels in patients with COVID-19. A combination of microvascular coagulation mechanisms and endotheliopathy are critical factors resulting in the death of COVID-19 patients.
Recent evidence has emerged suggesting that Ultra-large Von Willebrand Factor (ULVWF) multimers, increased VWF collagen types I and III, and decreased ADAMTS13 antigens and activity are all factors present in severely ill patients. VWF and ADAMTS13 both play roles in maintaining homeostasis in the microvasculature, and it is known that aging and obesity contribute to endothelial dysfunctions which result in an imbalanced ratio of VWF to ADAMTS13. This study further analyzed the VWF/ADAMTS13 axis in a diverse population of patients both with and without COVID-19 infections. Differences were observed in the activity levels and ratios between various VWF parameters, thrombin, and plasmin generation in patients that were positive for COVID-19 as compared to patients that were negative for COVID-19.
Related products available from Innovative Research also include: